Tuberculous Drug-induced Liver Injury and Treatment Re-challenge in Human Immunodeficiency Virus Co-infection

BACKGROUND: Tuberculosis drug-induced liver injury (TB-DILI) is the most common adverse event necessitating therapy interruption. The optimal re-challenge strategy for antituberculous therapy (ATT) remains unclear, especially in human immunodeficiency virus (HIV) co-infected individuals in high-prev...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Glob Infect Dis
Main Authors: Costiniuk, Cecilia T., Gosnell, Bernadett I., Manzini, Thandekile C., Du Plessis, Camille N., Moosa, Mahomed Yunus S.
Formato: Artigo
Idioma:Inglês
Publicado: Medknow Publications & Media Pvt Ltd 2015
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4693306/
https://ncbi.nlm.nih.gov/pubmed/26752869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0974-777X.170499
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares